Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Daniel S. Leventhal, Anna Sokolovska, Ning Li, Christopher Plescia, Starsha Kolodziej, Carey W. Gallant, Rudy Christmas, Jianrong Gao, Michael J. James, Andrés Abín-Fuentes, Munira Momin, Christopher G Bergeron, Adam Fisher, Paul Miller, Kip A. West, José M. Lora
Abstract
Synthetic biology is a powerful tool to create therapeutics which can be rationally designed to enable unique and combinatorial functionalities. Here we utilize non-pathogenic E coli Nissle as a versatile platform for the development of a living biotherapeutic for the treatment of cancer. The engineered bacterial strain, referred to as SYNB1891, targets STING-activation to phagocytic antigen-presenting cells (APCs) in the tumor and activates complementary innate immune pathways. SYNB1891 treatment results in efficacious antitumor immunity with the formation of immunological memory in murine tumor models and robust activation of human APCs. SYNB1891 is designed to meet manufacturability and regulatory requirements with built in biocontainment features which do not compromise its efficacy. This work provides a roadmap for the development of future therapeutics and demonstrates the transformative potential of synthetic biology for the treatment of human disease when drug development criteria are incorporated into the design process for a living medicine.